KEY TAKEAWAYS
- Q2 2026 revenue: $909K, up 61% sequentially and 115% YoY — a record quarter. Full-year guidance raised to $3.75M to $4.25M, implying 241% to 286% YoY growth. Gross margin: 84%. Active commercial cancer centers: 21, up more than 30% sequentially.
- Cash at June 30: $9.5M, down from $12.4M at Q1 end. Runway funds operations into late 2027. Cash flow breakeven requires approximately $5M in quarterly revenue — current run rate is roughly $1M per quarter. Management targets breakeven by Q4 2027.
- Phase III TIGeR-PaC trial enrollment completed in August 2026. Topline data expected in H2 2027. This is the binary event that determines whether RenovoRx becomes a multi-indication oncology platform or remains a niche device company. The stock doubled largely in anticipation of this data.
RenovoRx is a company with $909,000 in quarterly revenue that has more than doubled year-to-date. That gap between the revenue number and the stock move tells you everything about where the market is focused: not what the business is now, but what it could become if the Phase III trial data delivers. Understanding which of those things you're buying is the only analytical question that matters here.
What the company actually does
RenovoRx makes a device called RenovaCath. It's a dual-balloon catheter — a tube with two inflatable balloons — that doctors insert into the artery feeding a tumor. By inflating both balloons, the physician isolates a segment of the artery and can infuse chemotherapy directly into the tumor at a very high local concentration, while limiting the amount that reaches the rest of the body. The company calls this Trans-Arterial Micro-Perfusion, or TAMP.
The primary target: locally advanced pancreatic cancer, one of the deadliest and hardest-to-treat cancers. Standard treatment involves systemic chemotherapy — drugs delivered through the bloodstream that hit the whole body, not just the tumor — with severe side effects and limited efficacy. The TAMP approach aims to deliver a much higher drug dose directly to the tumor while reducing systemic toxicity. If the Phase III data confirms that it works better than standard treatment, RenovaCath becomes a standard-of-care option at major cancer centers. That's the outcome priced into a stock that's more than doubled while generating less than $1 million per quarter in revenue.
The commercial business right now
The commercial story is genuinely better than it was. Revenue went from $238K in Q4 2025 to $563K in Q1 2026 to $909K in Q2 2026. That's sequential growth of 136% and then 61%. Active cancer centers grew from 8 at the start of 2026 to 16 by Q1 to 21 by Q2 end, on a pipeline of 48 prospective sites. Management targets 36 active centers by year-end. The gross margin of 84% is exceptional for a device company at this scale — every additional dollar of revenue drops mostly to the gross profit line.
The repeat ordering dynamic is the most important commercial signal. When a physician places a second, third, fourth order for RenovaCath, it means the procedure is working well enough in practice to justify repeated use. CEO Shaun Bagai emphasized this repeatedly on the Q2 call: "When a physician places a second, third, and fourth order for RenovaCath it confirms the product is delivering an important treatment option and clinical utility for their patients." Q3 revenue is tracking to exceed Q2 based on those repeat order trends and the customer pipeline, management said.
The first commercial use for sarcoma — a solid tumor type other than pancreatic cancer — is also meaningful. It demonstrates the TAMP platform works across tumor types and potentially expands the addressable market well beyond pancreatic cancer even before the Phase III data arrives. The NIH clinical trials registry lists the TIGeR-PaC study details for anyone wanting the full protocol.
The cash math and what it requires
Cash at June 30: $9.5 million, down from $12.4 million at March 31. A $2.9 million burn in one quarter. Management says current cash funds operations into the second half of 2027. Breakeven requires approximately $5 million in quarterly revenue — roughly five times the current run rate. The full-year 2026 guidance of $3.75 to $4.25 million implies quarterly revenue averaging roughly $1 million, well below the breakeven threshold. That means RNXT will burn cash through all of 2026 and much of 2027, reaching breakeven only if the commercial ramp and the trial data both deliver on schedule.
The $9.5 million cash position is not a crisis. It's adequate runway for the next 12 to 15 months. But it does mean that if the TIGeR-PaC trial data in H2 2027 is negative or inconclusive, the company would need to raise additional capital to continue. That potential dilution is the structural risk hiding inside the "more than doubled" headline.
Why the stock doubled — and what it's pricing in
RNXT was trading around $0.70 in early 2026. By mid-August, after the Q2 earnings beat and Phase III enrollment completion announcement, it hit $1.40 — double. Two things drove the move. First: the commercial revenue acceleration was faster than the market expected. Going from $238K quarterly to $909K in two quarters, with 84% gross margins and explicit guidance that Q3 will be another record, is genuine fundamental improvement for a company at this stage. Second: enrollment completion in the Phase III TIGeR-PaC trial removed one major uncertainty. The trial is fully enrolled. The data will come. H2 2027 is the date. That binary event is now on the calendar rather than contingent on enrollment momentum.
The market cap even after the double is modest — roughly $60 to $70 million at $1.40 per share. For a clinical-stage oncology company with a Phase III trial reading out in 2027, that's actually a reasonable valuation if you believe the trial has meaningful probability of success. Pancreatic cancer has almost no effective treatment options. A device that demonstrably improves outcomes would address one of the largest unmet needs in oncology. The market is pricing in a non-trivial probability that TIGeR-PaC delivers. Whether that probability is correct depends entirely on the biology, which neither the stock chart nor the commercial revenue numbers can tell you.
The one thing beginners should take away
RNXT has doubled on two things: better-than-expected commercial traction and a Phase III trial that is now fully enrolled and on a defined timeline. The commercial business is real, growing, and has exceptional margins. The cash runway is adequate but not comfortable. The stock's upside from here depends almost entirely on what the TIGeR-PaC data shows in late 2027. If it's positive, RenovoRx becomes a company with a clinically validated platform and an addressable market orders of magnitude larger than what the current commercial revenue reflects. If it's negative, the commercial business alone supports a much smaller valuation. That's what you're deciding when you look at RNXT — not whether the company is doing well right now, but whether the binary event 15 months from now resolves favorably. The revenue growth is real. The bet is on the trial.